Zabetian, C.P.

patient mutation disease lrrk 2 parkinson carrier neurology 2019ser 1441c study idiopathic pd parkinsonism family symptom department university onset idiopathic substitution research lrrk 2 mutations frequency 1441h lrrk 2-associated pd disorder penetrance estimate analysis centre institute haplotype cause hospital parkinson disease population table article consortium stage medicine qsbb series kinase incidence control lrrk 2 gene series method group mutation carriers 10 years fference genetic scale london prevalence 79 years penetrance estimates www.neurology.org domain grant protein 2-associated ffected treatment clinic feature 69 years disease duration tremor pd onset di fference duration testing lrrk 2 protein ϯ sd age pathology figure r 1441h carriers health progression